ESTIMATED ANNUALIZED BURDEN HOURS

| Type of respondent | Form | Number of respondents | Number of responses per respondent | Average burden per response (in hours) | Total burden hours |
|---|---|---|---|---|---|
| Physician | CDC 4.422–1 | 200 | 1 | 10/60 | 33 |
| Total | | | | | 33 |

**Jeffrey M. Zirger,**

*Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.*

[FR Doc. 2020–01051 Filed 1–21–20; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

**[OMB No. 0970–0492]**

### Submission for OMB Review; Community Services Block Grant Annual Report

**AGENCY:** Office of Community Services; Administration for Children and Families; HHS.

**ACTION:** Request for public comment.

**SUMMARY:** The Administration of Children and Families (ACF), Office of Community Services (OCS) is requesting a three-year extension with minor changes of the Community Services Block Grant (CSBG) Annual Report (OMB No.: 0970–0492, expiration 1/31/2020). This request will support the currently utilized CSBG Annual Report, comprised of Modules 1–4, and incorporates performance management.

**DATES:** *Comments due within 30 days of publication.* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: *OIRA_SUBMISSION@OMB.EOP.GOV*, Attn: Desk Officer for the Administration for Children and Families.

Copies of the proposed collection may be obtained by emailing *infocollection@acf.hhs.gov.* Alternatively, copies can also be obtained by writing to the Administration for Children and Families, Office of Planning, Research, and Evaluation (OPRE), 330 C Street SW, Washington, DC 20201, Attn: OPRE Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection.

**SUPPLEMENTARY INFORMATION:**

*Description:* Module 1 includes minor edits to align with the updated, and OMB approved, CSBG State Plan. Module 2, Module 3, and Module 4 include only technical and grammatical updates for ease and clarity of current reporting. Copies of the proposed collection of information can be obtained by visiting: *http://www.acf.hhs.gov/programs/ocs/programs/csbg.*

*Respondents:* State governments, including the District of Columbia and the Commonwealth of Puerto Rico, and U.S. territories and CSBG eligible entities (Community Action Agencies).

*Annual Burden Estimates:*

| Instrument | Annual number of respondents | Annual number of responses per respondent | Average burden hours per response | Annual burden hours |
|---|---|---|---|---|
| CSBG Annual Report (States) | 52 | 1 | 198 | 10,296 |
| CSBG Annual Report (Eligible Entities) | 1,009 | 1 | 697 | 703,273 |

*Estimated Total Annual Burden Hours:* 713,569.

**Authority:** 112 Stat. 2729; 42 U.S.C. 9902(2).

**Mary B. Jones,**

*ACF/OPRE Certifying Officer.*

[FR Doc. 2020–00928 Filed 1–21–20; 8:45 am]

**BILLING CODE 4184–27–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket Nos. FDA–2018–E–3053 and FDA–2018–E–4226]**

### Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAVYRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.

**DATES:** Anyone with knowledge that any of the dates as published (see **SUPPLEMENTARY INFORMATION**) are incorrect may submit either electronic or written comments and ask for a redetermination by March 23, 2020. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by July 20, 2020. See ''Petitions'' in the